ABIOMED Announces Conference Call and Webcast to Discuss Fiscal
2006 First Quarter Financial Results
DANVERS, Mass., July 28 /PRNewswire-FirstCall/ -- ABIOMED, Inc. (NASDAQ:ABMD)
today announced that the Company will report financial results for the fiscal
first quarter that ended on June 30, 2005 on Thursday, August 4, 2005 before
the market opens. A conference call and webcast to discuss those results will
occur at 11:00 AM Eastern.
CONFERENCE CALL AND WEBCAST INFORMATION: To participate in this call within the U.S. and Canada, dial 866-250-3615;
international callers should dial 303-262-2004. The conference ID is 6020848. A replay of the call will be available four hours after the call and will be
available for one week. To access the replay within the U.S. and Canada, dial
888-203-1112; international callers should dial 719-457-0820. A webcast of the
call, which will be live and then archived for two weeks, will also be available
at http://www.abiomed.com/.
ABOUT ABIOMED Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a
leading developer, manufacturer and marketer of medical products designed to
assist or replace the pumping function of the failing heart. ABIOMED currently
manufactures and sells the AB5000(TM) Circulatory Support System and the BVS(R)
5000 Biventricular Support System for the temporary support of all patients
with failing but potentially recoverable hearts. In Europe, ABIOMED offers the
Impella(R) Recover(TM) minimally invasive cardiovascular support systems under
CE Mark approval. The Company's AbioCor(R) Implantable Replacement Heart was
the subject of an initial clinical trial under an Investigational Device
Exemption from the United States Food and Drug Administration. The AbioCor has
not been approved for commercial distribution, and is not available for use or
sale outside of the initial clinical trial. For additional information please
visit: http://www.abiomed.com/.
Contacts:
Liza Heapes Investor Relations Contact:
ABIOMED, INC. Rx Communications Group, LLC
Communications Specialist Melody A. Carey
978-646-1668 917-322-2571
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements
regarding development of ABIOMED's existing and new products, the Company's
progress toward commercial growth, and future opportunities. The Company's
actual results may differ materially from those anticipated in these forward-
looking statements based upon a number of factors, including uncertainties
associated with development, testing and related regulatory approvals,
anticipated future losses, complex manufacturing, high quality requirements,
dependence on limited sources of supply, competition, technological change,
government regulation, future capital needs and uncertainty of additional
financing and other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the Annual Report filed on
Form 10-K. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances that occur after the date of this Release or to reflect
the occurrence of unanticipated events. DATASOURCE: ABIOMED, Inc.
CONTACT: Liza Heapes, Communications Specialist of ABIOMED, INC., +1-978-646-1668, ; or Melody A. Carey of Rx Communications Group, LLC, +1-917-322-2571, Web site: http://www.abiomed.com/
|